Acer Therapeutics Inc Expected to Post Q1 2018 Earnings of ($0.69) Per Share (ACER)
Acer Therapeutics Inc (NASDAQ:ACER) – William Blair decreased their Q1 2018 EPS estimates for Acer Therapeutics in a report issued on Thursday. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will post earnings per share of ($0.69) for the quarter, down from their prior forecast of ($0.62). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Acer Therapeutics’ Q2 2018 earnings at ($0.83) EPS, Q3 2018 earnings at ($0.99) EPS, Q4 2018 earnings at ($1.18) EPS, FY2018 earnings at ($3.72) EPS and FY2019 earnings at ($2.07) EPS.
ACER has been the subject of a number of other reports. HC Wainwright set a $50.00 price target on shares of Acer Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 4th. ValuEngine cut shares of Acer Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research cut shares of Acer Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 9th. Finally, Roth Capital initiated coverage on shares of Acer Therapeutics in a research report on Monday, February 26th. They issued a “buy” rating and a $70.00 price target for the company. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $60.00.
Acer Therapeutics (NASDAQ:ACER) last issued its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.10).
A number of institutional investors and hedge funds have recently made changes to their positions in ACER. Ardsley Advisory Partners purchased a new stake in Acer Therapeutics in the fourth quarter valued at $212,000. Stonepine Capital Management LLC purchased a new stake in Acer Therapeutics in the fourth quarter valued at $1,385,000. J. Goldman & Co LP purchased a new stake in Acer Therapeutics in the fourth quarter valued at $1,496,000. Finally, Perceptive Advisors LLC purchased a new stake in Acer Therapeutics in the fourth quarter valued at $2,091,000. 7.54% of the stock is owned by hedge funds and other institutional investors.
About Acer Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.